Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma

  • Authors:
    • Barbara Vizio
    • Francesco A. Mauri
    • Adriana Prati
    • Pritesh Trivedi
    • Alice Giacobino
    • Anna Novarino
    • Maria Antonietta Satolli
    • Libero Ciuffreda
    • Michele Camandona
    • Guido Gasparri
    • Graziella Bellone
  • View Affiliations

  • Published online on: September 14, 2011     https://doi.org/10.3892/or.2011.1461
  • Pages: 69-76
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoresistance and self-renewal of cancer stem cells (CSC), found in many tumors including pancreatic ductal adenocarcinoma (PDAC), are believed to underlie tumor mass regrowth. The distribution of cells carrying the putative stem-cell markers CD133, Nestin, Notch1-4, Jagged1 and 2, ABCG2 and aldehyde dehydrogenase (ALDH1) was assessed immunohistochemically using PDAC and normal pancreas tissue microarrays. The immunoreactivity was semi-quantitatively graded against the normal pancreas and was correlated with the differentiation grade and disease stage. No statistical significant differences were found between normal pancreas and PDAC in the expression of Nestin, Notch1, 3 and 4, ABCG2 or ALDH1. Notch2 and Jagged1 and 2 expression were increased in PDAC. CD133-positive cells were above-normal in PDAC, but the difference was not statistically significant. Nestin, Notch1-4, Jagged1, ABCG2 and ALDH1 immunostaining scores were not correlated with tumor grade or disease stage. CD133 and Notch2 expression was significantly inversely correlated with tumor grade, but not disease stage. Notch3 immunostaining positively correlated with tumor stage, but not with differentiation grade. Jagged2 protein expression correlated inversely with disease stage, but not with tumor grade. From the clinical standpoint, improved delineation of the tumor CSC signature, putatively responsible for tumor initiation and recurrence after initial response to chemotherapy, may offer novel therapeutic targets for this highly lethal cancer.

Related Articles

Journal Cover

January 2012
Volume 27 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Vizio B, Mauri FA, Prati A, Trivedi P, Giacobino A, Novarino A, Satolli MA, Ciuffreda L, Camandona M, Gasparri G, Gasparri G, et al: Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncol Rep 27: 69-76, 2012
APA
Vizio, B., Mauri, F.A., Prati, A., Trivedi, P., Giacobino, A., Novarino, A. ... Bellone, G. (2012). Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma. Oncology Reports, 27, 69-76. https://doi.org/10.3892/or.2011.1461
MLA
Vizio, B., Mauri, F. A., Prati, A., Trivedi, P., Giacobino, A., Novarino, A., Satolli, M. A., Ciuffreda, L., Camandona, M., Gasparri, G., Bellone, G."Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma". Oncology Reports 27.1 (2012): 69-76.
Chicago
Vizio, B., Mauri, F. A., Prati, A., Trivedi, P., Giacobino, A., Novarino, A., Satolli, M. A., Ciuffreda, L., Camandona, M., Gasparri, G., Bellone, G."Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma". Oncology Reports 27, no. 1 (2012): 69-76. https://doi.org/10.3892/or.2011.1461